RYLAZE
Total Payments
$9.5M
Transactions
4,648
Doctors
1,519
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.3M | 1,748 | 747 |
| 2023 | $1.5M | 1,349 | 592 |
| 2022 | $3.0M | 1,126 | 483 |
| 2021 | $3.7M | 425 | 200 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.3M | 397 | 76.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.3M | 334 | 13.3% |
| Consulting Fee | $426,350 | 150 | 4.5% |
| Travel and Lodging | $228,926 | 646 | 2.4% |
| Food and Beverage | $206,884 | 3,095 | 2.2% |
| Space rental or facility fees (teaching hospital only) | $79,875 | 26 | 0.8% |
Payments by Type
Research
$7.3M
397 transactions
General
$2.2M
4,251 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AN OPEN-LABEL STUDY OF JZP-458 (RC-P) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)/LYMPHOBLASTIC LYMPHOMA (LBL) | JAZZ PHARMACEUTICALS INC. | $3.1M | 0 |
| AN OPEN-LABEL MULTICENTER STUDY OF RECOMBINANT CRISANTASPASE PRODUCED IN PSEUDOMONAS FLUORESCENS (RC-P) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)/LYMPHOBLASTIC LYMPHOMA (LBL) FOLLOWING HYPERSENSITIVITY TO E. COLI-DERIVED ASPARAGINASES | JAZZ PHARMACEUTICALS INC. | $2.5M | 0 |
| AN OPEN-LABEL, MULTICENTER STUDY OF RECOMBINANT CRISANTASPASE PRODUCED IN PSEUDOMONAS FLUORESCENS (RC-P) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)/LYMPHOBLASTIC LYMPHOMA (LBL) FOLLOWING HYPERSENSITIVITY TO E. COLI-DERIVED ASPARAGINASES | JAZZ PHARMACEUTICALS INC. | $777,922 | 0 |
| AN OPEN LABEL STUDY OF JZP 458 IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)/LYMPHOBLASTIC LYMPHOMA | JAZZ PHARMACEUTICALS INC. | $410,500 | 0 |
| A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy | JAZZ PHARMACEUTICALS INC. | $186,875 | 0 |
| Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents | JAZZ PHARMACEUTICALS INC. | $175,970 | 0 |
| IMMUNOLOGY OF ASPARAGINASE: A SYSTEMATIC REVIEW OF HYPERSENSITIVITY AND NEUTRALIZING ANTIBODY FORMATION | JAZZ PHARMACEUTICALS INC. | $74,737 | 0 |
| Phase 1, Open-Label, Dose-Finding, and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of JZP341 in Adult Participants With Advanced or Metastatic Solid Tumors | JAZZ PHARMACEUTICALS INC. | $62,325 | 0 |
| An Open-Label, Multicenter Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. Coli-derived Asparaginases | JAZZ PHARMACEUTICALS INC. | $6,500 | 0 |
Top Doctors Receiving Payments for RYLAZE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Tampa, FL | $7.4M | 432 |
| , MD | Pediatric Hematology-Oncology | Phoenix, AZ | $264,564 | 293 |
| , MD | Pediatric Hematology-Oncology | Memphis, TN | $228,347 | 138 |
| , D.O | Pediatric Hematology-Oncology | Salt Lake City, UT | $221,913 | 161 |
| , M.D | Pediatric Hematology-Oncology | Dallas, TX | $115,508 | 108 |
| , PPCNP-BC | Pediatrics | Seattle, WA | $102,827 | 140 |
| , MD | Pediatric Hematology-Oncology | Miami, FL | $88,631 | 65 |
| , MD | Pediatric Hematology-Oncology | San Antonio, TX | $87,309 | 67 |
| , MD | Pediatric Hematology-Oncology | Nashville, TN | $79,945 | 80 |
| , MD | Pediatric Hematology-Oncology | Tacoma, WA | $68,883 | 52 |
| , MD | Pediatric Hematology-Oncology | Hawthorne, NY | $55,888 | 50 |
| , RN, CNP | Family | Minneapolis, MN | $44,556 | 112 |
| , MD | Pediatrics | Louisville, KY | $39,019 | 23 |
| , MD | Pediatric Hematology-Oncology | Houston, TX | $32,530 | 21 |
| , M.D | Internal Medicine | Duarte, CA | $32,385 | 18 |
| Richard Drachtman | Pediatrics | New Brunswick, NJ | $31,944 | 20 |
| , MD | Pediatric Hematology-Oncology | Memphis, TN | $25,220 | 15 |
| , CPNP | Nurse Practitioner | St. Paul, MN | $25,088 | 34 |
| , MD | Pediatric Hematology-Oncology | Indianapolis, IN | $22,363 | 14 |
| , DO | Obstetrics & Gynecology | Charlotte, NC | $21,946 | 13 |
| , M.D | Pediatric Hematology-Oncology | Kansas City, MO | $20,716 | 13 |
| , M.D | Student in an Organized Health Care Education/Training Program | Boston, MA | $18,723 | 7 |
| Nancy Kuntz | Pediatrics | Orange, CA | $16,821 | 62 |
| , M.D.,PH.D | Hematology & Oncology | Boston, MA | $14,045 | 6 |
| , M.D | Pediatrics | San Francisco, CA | $13,407 | 13 |
Ad
Manufacturing Companies
- JAZZ PHARMACEUTICALS INC. $9.5M
- Jazz Pharmaceuticals Inc. $37,146
Product Information
- Type Drug
- Total Payments $9.5M
- Total Doctors 1,519
- Transactions 4,648
About RYLAZE
RYLAZE is a drug associated with $9.5M in payments to 1,519 healthcare providers, recorded across 4,648 transactions in the CMS Open Payments database. The primary manufacturer is JAZZ PHARMACEUTICALS INC..
Payment data is available from 2021 to 2024. In 2024, $1.3M was paid across 1,748 transactions to 747 doctors.
The most common payment nature for RYLAZE is "Unspecified" ($7.3M, 76.8% of total).
RYLAZE is associated with 9 research studies, including "AN OPEN-LABEL STUDY OF JZP-458 (RC-P) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)/LYMPHOBLASTIC LYMPHOMA (LBL)" ($3.1M).